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ABSTRACT 
Optimization of the Proteasomal Degradation Reporter (eDeg-
On) System for CRISPR-mediated Whole-genome Knockout 
Screens  
by 
Yiwen Liu 
Protein folding and clearance of misfolded proteins are crucial to maintain 
cellular homeostasis (Jariel-Encontre et al., 2008). Misfolded proteins may associate 
with other cellular components and possibly impair their functions. They may also 
self-associate to form insoluble aggregates, which are the hallmarks of a number of 
neurodegenerative diseases, such as Parkinson’s (Olanow and McNaught, 2006) and 
Alzheimer’s (Oddo, 2008). The ubiquitin proteasome system (UPS) is the main 
pathway that catalyzes the degradation of soluble misfolded proteins in mammalian 
cells. Therefore, enhancing the UPS activity through activation of proteasomal 
degradation is considered a promising strategy to ameliorate phenotypes associated 
with the accumulation of misfolded proteins. Modulation of specific UPS 
components, for instance, results in increased degradation of target proteins 
(Rechsteiner and Hill, 2005 and Vilchez et al., 2012). However, our current 
understanding of the molecular mechanism underlying proteasomal degradation is 
still limited, limiting the rational design of pharmacologic strategies to enhance UPS 
activity. As a result, proteasome activators are rare and remain poorly characterized 
(Huang and Chen, 2009).   
 
 
To overcome these limitations, researchers in my group developed a cell-
based platform (the eDeg-On system) to monitor changes in UPS activity. This 
genetic circuit links increase in UPS activity to an increase in fluorescent output, 
thereby providing a reliable tool for the discovery of proteasome activators. The 
CRISPR-cas technology has emerged as powerful technique to introduce genetic 
modifications at the whole-genome scale. I optimized the eDeg-On system and 
evaluated it for pooled screening of whole-genome CRISPR-mediated knockout 
library. I replaced the antibiotic resistance gene in the eDeg-On system and assessed 
the response of HEK293 cells stably expressing the eDeg-On system to modulation 
of proteasomal degradation. To evaluate the use of a stable cell line expressing the 
eDeg-On system as a reporter assay in the context of a pooled CRISPR-mediated 
screen, I conducted mock screens using different ratios of positive and negative 
controls. The results obtained demonstrate that the eDeg-On system can be used as 
a reporter assay for CRISPR-mediated whole-genome knockout screens.  
The use of the eDeg-On system to conduct genetic screen for the discovery of 
molecules that function as proteasome regulators will contribute to the 
development of therapeutic strategies for protein misfolding diseases. Further 
applications of this study include targeting the UPS function for therapeutic 
applications as well as for enhancing the production of recombinant proteins in 
industrial settings. 
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Chapter 1 
Introduction 
The ubiquitin proteasome system (UPS) plays an important role in degrading 
misfolded and damaged proteins and maintaining cellular homeostasis. 
Accumulation of misfolded and aggregated proteins is the hallmark of a number of 
neurodegenerative diseases, such as Parkinson’s (Olanow and McNaught, 2006), 
Huntington’s (Ortega et al., 2007) and Alzheimer’s (Oddo, 2008). Enhancing 
proteasomal degradation is considered a promising strategy to ameliorate the 
phenotypes associated with diseases characterized by aberrant accumulation of 
proteinaceous aggregates (protein misfolding diseases). Our limited understanding 
of the regulatory mechanisms underlying activation of UPS function, however, 
precludes the rational design of pharmacological strategies to increase proteasomal 
degradation. As a result, proteasome activators are rare and remain poorly 
characterized.  
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1.1.  The Ubiquitin Proteasome System 
The UPS is one of the main intracellular proteolytic machineries that 
maintain protein homeostasis by mediating degradation of misfolded and damaged 
proteins. It is also involved in regulating the half-lives of proteins, thereby 
participating in key processes such as gene expression, cell cycle, and tumor 
development (Jariel-Encontre et al., 2008). Proteins targeted for degradation are 
labeled with ubiquitin (Ub) molecules, unfolded, and inserted into the proteasome 
for cleavage. The UPS is composed of the 26S proteasome, ubiquitin activating 
enzymes (E1), ubiquitin conjugating enzymes (E2), and ubiquitin ligases (E3) that 
mediate ubiquitination of substrate proteins (Figure 1.1). The 26S proteasome 
includes the 20S core particle (CP) and the 19S regulatory particles (RP). The 
~700kDa barrel-shaped 20S CP is composed of 28 subunits (Rechsteiner and Hill, 
2005 and Kish-Trier and Hill, 2013). Three active sites with trypsin-like, 
chymotryptsin-like, and caspase-like activities are embedded in the center of the 
barrel (Rechsteiner and Hill, 2005). Two ATP-independent activators (PA28 and 
PA200) and one ATP-dependent activator (the 19S RP, also known as PA700) 
regulate the 20S CP.  
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Ubiquitination of proteins targeted for degradation proceeds through three 
steps (Figure 1.1): i) activation of ubiquitin catalyzed by an E1 enzyme; ii) 
conjugation of the activated ubiquitin to an E2 enzyme; iii) transfer of the activated 
ubiquitin from the E2 enzyme to the substrate catalyzed by an E3 ligase (Kleiger and 
Mayor, 2014, Scheffner et al., 1995 and Weissman et al., 2011). Depending on the 
ubiquitination patterns, the substrate may be internalized into the lysosome and 
degraded by the lysosomal hydrolytic enzymes or may be directed to the 26S 
proteasome for proteasome-mediated degradation (Kommander, 2009). In addition 
to the ubiquitin-dependent pathway, a ubiquitin-independent pathway also exists 
and mediates the degradation of aged, oxidized, or unfolded proteins (Jariel-
Encontre et al., 2008).  
1.2. Proteasome Modulators: Inhibitors and Activators 
Proteasome inhibitors have been widely used in research (Huang and Chen, 
2009) and have transitioned to clinical therapeutics (Burger and Seth, 2004). Both 
natural and synthetic inhibitors have been identified. Naturally occurring 
 
Figure 1.1. Overview of the UPS. 
Protein degradation is mediated 
by the UPS through sequential 
steps: i) activation of Ub mediated 
by the ubiquitin activating 
enzyme (E1); ii) Ub conjugation to 
the Ub-conjugating enzyme (E2); 
iii) Ub transfer from E2 to the 
substrate; iv) Ub chain elongation; 
v), degradation of polyUb-tagged 
substrates via the 26S 
proteasome.  
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proteasome inhibitors are classified as small molecule compounds such as 
tyropeptin A, PR39, lactacystin and epoxomicin (Huang and Chen, 2009), and 
macromolecular proteins, which are few and poorly characterized. Synthetic 
inhibitors include peptide aldehydes, reversible inhibitors such as leupeptin and 
MG-132, and irreversible inhibitors that form covalent bonds with the peptidase 
sites of the proteasome (Sander and Joung, 2014). Structural analyses helped 
decipher the mechanism of inhibition and enabled the rational design of both 
reversible and irreversible inhibitors with improved function (Bogyo and Wang, 
2002).  
A limited number of chemical activators of proteasomal degradation have been 
reported but remain poorly characterized. Denaturing reagents, lipids, and peptide-
based molecules may activate the proteasome when present at high concentrations, 
but also induce significant toxicity (Huang and Chen, 2009). Oleuropein and 
betulinic acid were also reported to activate the proteasome (Huang and Chen, 
2009). Oleuropein can activate all three hydrolytic sites, while betulinic acid 
activates the chymotrypsin-like active site without affecting the trypsin-like and 
caspase-like sites (Huang and Chen, 2009). Two other small molecules, AM-404 and 
MK-866, were recently discovered from the NIH NCC collection through a series of 
in vitro and in cellulo assays as proteasome agonists (Trader et al., 2017).  
Three macromolecular protein complexes, PA28/11S REG, PA200/Blm10 and 
PA700/19S RP, are involved in the regulation of proteasome activity. Both PA28 and 
PA200 can bind to the 20S core and facilitate opening of the proteasome entrance 
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gate (Lee et al., 2010). The biological roles of PA28 and PA200 remain elusive. They 
are hypothesized to bind to each side of the proteasome barrel with synergistic 
effect (Rechsteiner and Hill, 2005). PA200 was reported to regulate the cellular 
localization of the 20S proteasome, but its physiological function remains unclear 
(Rechsteiner and Hill, 2005).  
Overexpression of the 19S RP subunit PSMD11 was found to increase UPS 
activity and promote 26S assembly (Rechsteiner and Hill, 2005). The expression of 
PSMD11 is further regulated by the insulin/insulin-like growth factor-I FOXO4 in a 
cell-type dependent manner (Vilchez et al., 2012). Structural analyses demonstrate 
that PSMD11 contacts the C-termini of the 20S subunits and contributes to the 
overall stability of the 26S complex (Vilchez et al., 2012a). Overexpression of 
PSMD11 in C. elegans enhances protection against proteolytic stress and increases 
the longevity of the worm (Vilchez et al., 2012b). Disruption of PSMD11 causes 
death in S. cerevisiae (Kish-Trier and Hill, 2013). Further research demonstrated 
that phosphorylation of PSMD11 at the Serine 14 via the c-AMP pathway further 
enhances proteasome degradation (Lokireddy et al., 2015). 
Deubiquitinating enzymes or deubiquitinases (DUBs) are also essential 
regulators of UPS function. They mediate removal of ubiquitin from substrates and 
participates in ubiquitin maturation, recycling, and editing (Huang and Chen, 2009 
and Pfoh et al., 2015). They belong to the superfamily of proteases and can be 
further classified into five sub-classes based on the structure of their catalytic 
domains (Nijman et al., 2005). Among the five sub-classes, the ubiquitin-specific 
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proteases (USP) mediate ubiquitin-dependent protein degradation and display 
specificity for different substrates and E3 ligases. The yeast DUB Ubp6p and its 
mammalian homolog USP14 was shown to inhibit proteasome function via binding 
to the 19RP and to inhibit protein turnover, although the exact mechanism remains 
elusive (Hu et al., 2005 and Lee et al., 2010). The discovery that the deubiquitinating 
enzyme USP14 inhibits degradation of ubiquitinated substrates (Hanna et al., 2006) 
has led to the discovery of the proteasome activator IU1, a small-molecule inhibitor 
that selectively targets the activated form of USP14 (Lee et al., 2010). This study 
provides proof-of-principle demonstration of pharmacologic activation of 
proteasomal degradation. 
Some ubiquitin ligases may also function as proteasome activators. The E3 
ubiquitin ligase Parkin activates the 26S proteasome by promoting the interaction 
between the N-terminal ubiquitin-like domain and the 19S subunits (Saito et al., 
1997). Mutations in parkin gene are associated with the early-onset autosomal-
recessive familial Parkinson’s disease, which is characterized by accumulation of 
misfolded and aggregated proteins (Um et al., 2010). Overexpressing C-terminus of 
the E3 ligase HSC70-interacting protein (CHIP) enhances degradation of Huntingtin, 
a protein that forms aggregates in association with the development of the 
Huntington’s disease (Um et al., 2010). Overexpression of CHIP also promotes the 
degradation of p53 (Jana et al., 2005).  
Despite increasing evidence describing the role of endogenous proteins in the 
regulation of proteasomal degradation, we are currently unable to rationally design 
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activators of UPS activity. This lack of knowledge motivates the development of 
high-throughput screens to identify UPS targets for activation of protein 
degradation.  
1.3. The eDeg-On System: A Genetic Inverter for Monitoring 
Enhancement of UPS Activity 
My lab has previously devised an orthogonal genetic circuit, the eDeg-On system 
(Figure 1.2), which links enhancement of UPS activity to an easily detectable 
fluorescent output (Zhao et al., 2014). Unlike other fluorescent protein reporters 
that link proteasomal degradation to a decrease in protein fluorescence (Dantuma 
et al., 2000, Li et al., 1998, and Hamer et al., 2010), the eDeg-On system is based on a 
positive correlation between activation of degradation and increase in GFP signal. 
The tetracycline repressor (TetR) was engineered to function as a UPS substrate by 
fusion to a degradation tag. Specifically, TetR was fused to the 16-residue CL1 
hydrophobic peptide that mediates degradation of the fusion protein via the 
ubiquitin-dependent pathway (Gilon et al., 2000), or to the ODC, the 37-amino acid 
C-terminal sequence of ornithine decarboxylase that mediates degradation of the 
fusion protein via the ubiquitin-independent pathway (Dantuma et al., 2000). The 
circuit was then optimized using the tetracycline-controlled transactivator (tTA), a 
transcription factor that can function either as a repressor when bound to the 
tetracycline operator (TO) placed downstream of the promoter, or as an activator 
when bound to seven cassettes of TO placed upstream of a minimal CMV promoter 
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(Li et al., 1998). A tTA-based self-activation loop was included in the circuit to 
enhance the sensitivity and dynamic range of the output signal.  
The CL1 degradation tag was discovered in the context of a yeast screen 
designed to isolate sequences that would destabilize the cytosolic yeast protein 
Ura3p, resulting in its degradation though the Ubc6p/Ubc7p system (Gilon et al., 
1998). The CL1 tag was used to study ubiquitin-dependent degradation using fusion 
proteins such as Ura3p-CL1 in yeast and GFP-CL1 in mammalian cells and C. elegans 
(Metzger et al, 2008, Bence et al, 2001 and Link et al, 2006). The E3 ligase involved 
in the CL1 degradation pathway is Doa10 (yeast)/TEB4/March6 (human homolog) 
(Metzger et al., 2008), but the interacting DUB responsible for removing the 
ubquitin from the substrate in the CL1 degradation pathway has not been identified. 
A number of E3 ligases and DUBs mediating March6 degradation or CL1-
independent March 6 substrate degradation have been identified, including WSB-1, 
USP19 and USP33 (Zavacki et al., 2009 and Nakamura et al, 2014).  
The eDeg-On system (Zhao et al., 2014) is comprised of three plasmids: i) a 
plasmid expressing tTA fused to either the CL1 or the ODC degradation tag (tTA-
Deg) under the control of a strong promoter (CMV) (ptTA); ii) a plasmid expressing 
tTA-Deg under a minimal promoter (Pmin) activated by tTA for output signal 
amplification (pTRE_tTA); and iii) a plasmid expressing GFP under the control of the 
tetracycline operator (TO) for fluorescence output (pTO_GFP). The eDeg-On system 
can be calibrated using tetracycline (Tc) to enable sensitive detection of a wide 
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range of UPS activation levels. 
 
1.4. CRISPR-cas System: Genome-editing Technology 
The CRISPR-cas technology has emerged as a tool to introduce genetic 
modification in the chromosome. Discovered in bacteria, clustered, regularly 
interspaced, short palindromic repeat (CRISPR) sequences are processed by 
CRISPR-associated protein nucleases (cas) to target invading foreign DNA, such as 
viruses and plasmids (Sampson and Weiss, 2014). The CRISPR system has been 
adopted for genome engineering purposes and it is typically based on the use of the 
Streptococcus pyogenes single cas9 nuclease (Sander and Joung, 2014).  
In addition to the cas9 nuclease, the CRISPR-cas system also requires a guide 
RNA (gRNA) comprised of two RNA segments: a sequence complementary to the 
genomic sequence to be cleaved (CRISPR RNA or crRNA), and a transactivating 
CRISPR RNA (tracrRNA) to mediate formation of a complex between the genomic 
DNA and cas9 (Sander and Joung, 2014). As a complex, the cas9 protein and the 
Figure 1.2. Diagram of the eDeg-On 
system.  
The eDeg-On system contains three 
plasmids: ptTA for the expression of the 
tetracycline repressor variant (tTA) with a 
degradation tag (CL1 or ODC) under a 
strong promoter (CMV) with hygromycin 
resistance; pTRE_tTA for the expression of  
a self-activation loop of tTA under a 
minimal promoter (Pmin) for output 
signal maximization; and pTO_GFP for the 
expression of GFP under the control of  the 
tetracycline operator (TO) for fluorescence 
output (Zhao et al., 2014). 
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engineered gRNA can target and cleave double-stranded DNA in any genomic 
region, including coding sequences, promoters, and regulatory elements. Two 
different DNA repair pathways are responsible for repairing the double strand 
break introduced by the cas9/gRNA complex, and introduce different mutations into 
the genome. Random insertions/deletion (indel) mutations are introduced via the 
nonhomologous end joining (NHEJ) DNA repair pathway, resulting in premature 
stop codon or out of frame mutations that knock out the gene (Sander and Joung, 
2014). Alternatively, a sequence of interest can be inserted in the genome through 
the homology-directed repair (HDR) pathway at a site targeted by the gRNA (Sander 
and Joung, 2014). The sites targeted with gRNA can either locate in the middle of an 
exon to allow the precise insertion of an exon sequence with a specific mutation 
(Gratz et al., 2014 and Lin et al., 2014) or downstream of a gene of interest to fuse 
the gene of interest to a tag or to a reporter gene (Gratz et al., 2014 and Yang et al., 
2013).  
CRISPR also has applications beyond genome editing. Cas9 harboring the D10A 
and H840A substitutions lacks endonuclease activity: this “dead” cas9 (dcas9) can 
be used as a genome interference tool for transcriptional repression and activation 
(Qi et al., 2013, Cong et al., 2013, Mali et al., 2013 and Larson et al., 2013). Dcas9 
does not introduce double strand breaks into the genomic sequence due to the lack 
of endonuclease activity, but binds to the genomic region complementary to gRNA 
and helps recruit repressors or activators when bound to the promoter region. For 
transcriptional activation, dcas9 can be coupled with engineered transcription 
activation domains, such as antibody epitope-fused VP64 chains or a combination of 
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VP64, HSF1, and p65 activation domains (Heckl and Charpentier, 2015). To achieve 
transcription repression, dcas9 is usually fused to repressive chromatin-modifying 
complexes such as the Krüppel-associated box(KRAB) domain (Gilbert et al., 2013).  
The CRISPR technology has been used not only to introduce individual gene 
modifications in a variety of prokaryotic and eukaryotic organisms including 
microorganisms, animals, plants (Sanger and Joung, 2014), and even human 
embryos (Liang et al., 2015), but also to achieve whole-genome scale modifications 
in human and mouse cell lines (Shalem et al., 2014, Wang et al., 2014, Hart et al., 
2015, Ma et al., 2015, Doench et al., 2016 and Tzelepis et al., 2016). CRIPSR-cas 
lentiviral libraries containing gRNAs for all nonessential genes have been 
introduced to mammalian cell lines, and subpopulations presenting desired 
properties, such as drug resistance, were isolated and subjected to next-generation 
sequencing (Wang et al., 2014 and Shalem et al., 2014 and Sanjana et al., 2014).  
1.5. GeCKO Library and Applications 
A number of CRISPR-based libraries were developed to introduce indel 
mutations throughout the entire genome and to achieve whole-genome knockout. 
Among these pooled libraries, the second generation of the human genome-scale 
CRISPR-Cas9 knockout (GeCKOv2) library is of special interest because it provides 
broad coverage of the human genome and miRNAs (Sanjana et al., 2014). This 
lentivirus-based library is divided into two sub-libraries with each sub-library 
containing three gRNAs per gene that can be used for smaller-scale knockout 
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screens. This GeCKOv2 library can be introduced into the HEK293/eDeg-On cells for 
the identification of proteasome modulators that enhance proteasome activity upon 
knockout.  
The GeCKOv2 library has been utilized in a variety of screening strategies 
(Shalem et al., 2015). It is mostly used for genome-wide drug resistance screens, 
where a primary cell line is transduced with GeCKOv2 library and treated with the 
drug of interest to select genes involved in the cell response to drug treatment. The 
GeCKOv2 library can also be introduced into a stable cell line in which the 
expression of a fluorescence reporter is linked to a gene of interest to identify genes 
that affect the expression of the gene of interest via fluorescence-activated cell 
sorting (FACS).  
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Chapter 2 
Results 
 
2.1. Establishing HEK293/eDeg-On_2 Stable Cell Lines 
The current eDeg-On system is based on the use of puromycin as antibiotic 
selection marker and it cannot be used to screen the GeCKOv2 library, which is also 
based on puromycin selection. To overcome this limitation, the puromycin cassette 
in the plasmid expressing tTA (ptTA) was replaced with a hygromycin cassette, 
generating the plasmid ptTA_2. Standard restriction enzyme cloning was used to 
replace the puromycin resistance gene with the hygromycin resistance gene (Figure 
2.1), and the sequence was verified by Sanger sequencing. 
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To establish a new cell line with chromosomal integration of the eDeg-On_2 
system, a cell line stably transfected for the expression of the TO_GFP cassette was 
developed first. HEK293 cells were transfected with pTO_GFP, cultured in the 
presence of zeocin for three weeks, and sorted to select the top 20% of cells 
presenting highest GFP expression. The resulting cells (HEK293/TO_GFP_2 cells) 
were co-transfected with ptTA_2 and pTRE_tTA, cultured in the presence of 
hygromycin and blasticidin, and sorted to select the 20% of cells presenting the 
lowest GFP expression. Sorted cells (HEK293/eDeg-On_2) were plated at 0.5 
cell/well in 96-well plates to isolate monoclonal populations. Single clones (Figure 
2.2a) were first treated without Tc and with 1 μg/ml Tc to monitor changes in GFP 
fluorescence in response to changes in Tc via flow cytometry (Figure 2.2b). It is 
expected that cells will not display fluorescence when tTA is bound to the TO 
operator upstream of GFP, and that when tTA is not bound to the TO operator, cells 
will display high fluorescence. The fluorescence signal is expected to increase as a 
function of the extent of tTA displacement from the operator to a maximum equal to 
the GFP fluorescence of the HEK293/TO_GFP_2 cells. However, GFP expression was 
found to be leaky, as signal was detected in the absence of Tc, suggesting basal 
expression of GFP in the presence of tTA. GFP expression at high Tc concentration is 
Figure 2.1. The eDeg-On_2 system. 
 The eDeg-On_2 system is composed 
of three plasmids: i) ptTA_2 
containing the hygromycin selection 
marker; ii) pTRE_tTA containing the 
blasticidin marker; and iii) pTO_GFP 
containing the zeocin marker.  
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also found to be lower than that of the parental HEK293/TO_GFP_2 cells, suggesting 
residual binding of Tc-bound tTA to the operator, as expected (Zhao et al., 2014). 
Single clones presenting increase in GFP fluorescence upon addition of Tc equal or 
higher than half of the theoretical expected increase were selected for further 
analyses. 
 
The fluorescence of selected HEK293/eDeg-On_2 single clones was also 
evaluated in response to treatment with the proteasome inhibitor MG132 (Figure 
2.3). All clones were tested without Tc or with 0.2 μg/ml Tc and with 3 M of 
MG132. With the exception of clone 355, all cells treated with MG132 showed a 1.6-
fold or higher decrease in fluorescence when treated with 0.2 μg/ml Tc, suggesting 
that these clones are sensitive to decrease in proteasome activity.  
a
  
b
  
Figure 2.2. Fluorescence of isolated HEK293/eDeg-On_2 single clones.  
a, Example of a single clone with a single peak in fluorescence without Tc; x-axis, GFP 
fluorescence; y-axis, cell number. b, GFP fluorescence intensity of single clones reported as 
ratio of cell fluorescence in the presence of Tc to cell fluorescence of untreated cells; clones 
presenting increase in GFP fluorescence upon addition of Tc equal or higher than half of the 
theoretical expected increase (red line) were selected for further analyses; y-axis, fold change 
in fluorescence.  
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The HEK293/eDeg-On_2 clone #198 was selected as a candidate to test the 
proteasome activator PSMD11. PSMD11 was found to upregulate proteasome 
activity via phosphorylation, and the phosphomimetic PSMD11-S14D mutant can 
further enhance proteasome activation (Lokireddy et al., 2015). Cells transfected 
with a plasmid expressing PSMD11 displayed a 30% increase in GFP fluorescence, 
and cells transfected with a plasmid expressing PSMD11-S14D mutant showed a 
38% significant increase in GFP fluorescence (Figure 2.4) compared to cells 
transfected with the control plasmid (pcDNA3.1+). This result suggests that the 
eDeg-On_2 system can detect proteasome activation induced upon overexpression 
of PSMD11 and PSMD11-S14D. 
Figure 2.3.GFP fluorescence of HEK293/eDeg-On_2 single clones in response to 
treatment with the proteasome inhibitor MG132. 
 Relative GFP fluorescence values were calculated by normalizing the fluorescence of treated 
cells to that of control cells cultured without Tc or MG132.  
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2.2. Verifying CRISPR-mediated Knockout Controls 
Positive controls for the knockout screen based on introducing the CRISPR-
mediated library to HEK293/eDeg-On_2 cells were established. A lentiviral plasmid 
(pLentiCRISPRv2) was generated to target a single gene (Figure 2.5). It contains the 
20bp gRNA complementary to the knockout region and the cas9 sequence for DNA 
cleavage. It also contains a puromycin selection marker for selection purposes. Two 
different gRNAs were designed and inserted into the lentiCRISPRv2 vector: a) the 
gRNA targeting tTA, and b) a control nontargeting (NT) gRNA, a 20bp gRNA 
sequence that does not target any known coding sequence in the human genome.  
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Figure 2.4. GFP fluorescence output of 
HEK293/eDeg-On_2 clone #198 upon 
overexpression of PSMD11 and PSMD11-
S14D.  
GFP fluorescence of cells transfected with 
PSMD11-S14D, PSMD11 and pcDNA3.1+ 
(control) plasmids were measured without and 
with 0.2 μg/ml Tc. Relative GFP fluorescence 
values were calculated by normalizing the 
fluorescence of cells transfected with PSMD11 or 
PSMD11-S14D plasmids to that of cells 
transfected with the control plasmid without Tc.  
  
* * 
Figure 2.5. pLentiCRISPRv2 with gRNA of interest.  
plentiCRISPRv2 contains the 20bp gRNA complementary to a specific sequence in the 
gene targeted for knockout, the cas9 gene for DNA cleavage, and the puromycin 
resistance cassette. 
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The effect of tTA knockout on GFP fluorescence was evaluated in 
HEK293/eDeg-On_2 cells. The GFP fluorescence of cells transduced with viruses 
expressing tTA-specific gRNA was found unchanged upon Tc dosage, while the GFP 
fluorescence of cells transduced with viruses expressing non-targeting gRNA 
increased as a function of Tc concentrations (Figure 2.6). This result suggests that 
CRISPR-mediated tTA knockout alters the GFP expression of the eDeg-On_2 system.   
 
2.3. Titration of CRISPR-mediated Knockout Viruses 
Virus titration was conducted to determine the amount of virus needed to 
transduce cells such that >90% of transduced cells receives only one copy of virus 
per cell. Three titration methods are most commonly used: a) RNA titration to 
assess the copy number of viral genome in the viral supernatant; b) DNA titration to 
quantify viral integration into the mammalian host genome; c) functional titration to 
evaluate the expression of the transgene (a fluorescence reporter gene or a gene 
conferring antibiotic resistance) encoded in the viral genome (Sastry et al., 2002).  
Figure 2.6. Transduction of 
HEK293/eDeg-On_2 clone #198 
with NT and tTA gRNA viruses.  
HEK293/eDeg-On_2 cells were 
transduced with equal number of 
virus particles of NT or tTA gRNA 
viruses and selected using 
puromycin at 1 μg/ml for one week. 
Cells were replated and treated with 
different Tc concentrations for 24 
hours before analysis on flow 
cytometry. All GFP fluorescence was 
normalized to that of NT-gRNA virus 
transduced cells without Tc.  
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The RNA titration method was used in this study to estimate the titers of tTA 
and NT gRNA viruses. The titers (number of virus particles per volume) of different 
gRNA viruses were found to be in the same order of magnitude (Figure 2.7). The 
RNA titration method was reported to overestimate the real titer, because the RNA 
titer also takes defective viral particles into account (Scherr et al., 2001, Sastry et al, 
2002 and Geraerts et al., 2006). 
 
Compared to the RNA titration method, the functional titration method, 
which is typically based on a measurement of fluorescence or cell survival, was 
reported to provide a more accurate estimate of the number of viable viral particles 
(Sastry et al., 2002). Because the GeCKOv2 lentiviral plasmids contain gene 
conferring antibiotic resistance, the functional titer in this study was determined by 
monitoring cell viability after antibiotic selection of transduced cells. Poisson 
statistics helps to establish links between cell viability and the multiplicity of 
infection (MOI), which is defined as the ratio of viral particles to transduced cells 
(Shabram and Aguilar-Cordova, 2000). Based on Poisson distribution, conducting 
Figure 2.7. Titers for tTA and NT gRNA 
viruses.  
Y axis, virus titer (transducing unit per microliter 
of concentrated virus).  
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transduction at an MOI of 0.2 allows approximately 90% of the cells surviving 
antibiotic selection to be transduced with only one copy of virus (Sanjana et al., 
2014). The amount of concentrated virus equivalent to an MOI of 0.2 for a total of 
8*104 transduced cells with either NT and tTA gRNA virus was determined to be 6 
L, and this amount was scaled up for mock screen studies.  
2.4. Mock Screen in HEK293/eDeg-On_2 Cells 
2.4.1. Experiment 1: Transduction of HEK293/eDeg-On_2 cells with 
different ratios of NT and tTA gRNA viruses 
To evaluate whether the eDeg-On_2 system can be used to distinguish the 
fraction of cells in which tTA is knocked out by monitoring changes in the cell 
fluorescence output, HEK293/eDeg-On_2 cells were transduced with NT gRNA virus, 
tTA gRNA virus, or different ratios of a NT/tTA gRNA virus mixture. Cells 
transduced with tTA gRNA viruses showed an 18-fold increase in GFP fluorescence 
compared to cells transduced only with NT gRNA virus (Figure 2.8). Cells 
transduced only with NT gRNA viruses were used as negative control, and the 1% 
gate was established by the top 1% cells with highest fluorescence in the negative 
control cells. The number of cells above the 1% gate was monitored and the 
numbers of expected hits and actual hits in cells above the gate were calculated 
(Table 2.1). The expected hits were defined as positive control cells (cells 
transduced only with tTA gRNA virus) that was expected to be in the gated 
population and the number of expected hits was calculated by multiplying the 
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number of cells above the 1% gate in cells transduced only with tTA gRNA viruses 
by the tTA gRNA: NT gRNA virus transduction ratio. The actual hits were defined as 
cells experimentally measured in the gated population that were not false positives 
and was calculated by subtracting the number of cells above 1% gate among the 
population of cells transduced only with NT gRNA virus (false positives) from the 
number of cells above 1% gate among cells transduced with the virus mixture. For 
the ratios of NT gRNA: tTA gRNA of 1000:1 and 100:1, the eDeg-On_2 system was 
found to detect changes in the number of cells above the 1% gate, and the numbers 
of expected hits and actual hits were similar. However, the eDeg-On_2 system could 
not be used to distinguish cells transduced with tTA gRNA viruses from cells 
transduced with NT gRNA viruses at 10000:1 ratio.  
 
 
Figure 2.8. Normalized GFP fluorescence of cells transduced only with NT 
or tTA gRNA virus. 
 HEK293/eDeg-On_2 cells were transduced with only NT or tTA gRNA virus 
and treated without and with 0.04 μg/ml Tc. The mean GFP fluorescence was 
measured in flow cytometry and normalized to the GFP fluorescence of cells 
treated with 0.04 μg/ml Tc.  
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Table 2.1.Mock screen experiment 1 results. 
- Tc Tc=0.04 μg/ml 
Sample 
# Cells 
above 1% 
gate 
# 
Expected 
hits 
# Actual 
hits 
Sample 
# Cells 
above 1% 
gate 
# 
Expected 
hits 
# Actual 
hits 
NT only 1041 - - NT only 1017 - - 
100:1 2836 1361 1795 100:1 3103 251 2086 
1000:1 1207 1073 166 1000:1 1130 25 113 
tTA only 31998 - - tTA only 25129 - - 
 
To detect weaker proteasome activators, the eDeg-On_2 system may be fine-
tuned with Tc to adjust detection sensitivity. To evaluate the effect of Tc on the 
output signal, transduced cells were treated with 0.04 μg/ml Tc. Cells transduced 
with tTA gRNA virus and treated with 0.04 μg/ml Tc display a 5.6-fold increase in 
GFP fluorescence compared to cells transduced only with NT gRNA virus (Figure 
2.8). Similar results were obtained for cells transduced using 100:1 and 1000:1 
ratios of NT gRNA: tTA gRNA viruses in the presence of 0.04 μg/ml Tc (Table 2.1), 
suggesting that the eDeg-On_2 system may be used to distinguish cells transduced 
with tTA gRNA virus from cells transduced with NT gRNA virus in the presence of 
0.04 g/ml of Tc.  In conclusion, the eDeg-On_2 system can detect a minimum ratio 
of 1000 to 1 between cells transduced with NT- and tTA-gRNA virus either without 
Tc treatment or with 0.04 μg/ml Tc.  
2.4.2. Experiment 2: Evaluation of the signal of the eDeg-On_2 system using 
different ratios of cells treated with different amounts of Tc 
The previous experiment provided information on the signal of the eDeg-
On_2 system when strong proteasome activators similar to that of tTA knockouts 
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are available. Weaker knockout controls than the tTA knockout are needed so that 
the eDeg-On_2 system can be evaluated under different levels of proteasome 
activation. However, we lack such a positive control. Instead of testing proteasome 
activators upon knockout, it is possible to directly test whether cells with increased 
fluorescence can be distinguished from a larger population of cells with basal 
fluorescence. 
To evaluate whether the eDeg-On_2 system can distinguish a small fraction of 
cells with increased fluorescence from a population of cells with basal fluorescence, 
HEK293/eDeg-On_2 cells were treated with different concentrations of Tc, and the 
GFP fluorescence was measured using flow cytometry (Figure 2.9). Cells treated 
with 0.04 μg/ml Tc were used as negative control and were mixed with cells treated 
with a higher Tc concentration (0.1 or 1 μg/ml) at different ratios (100:1 and 
1000:1). A 1% gate was established by the top 1% cells displaying highest 
fluorescence among the population of negative control cells. The number of cells 
above the gate, the number of expected hits and the number of actual hits were 
quantified (Table 2.2). For both mixtures of cells treated with ratios of low (0.04 
g/ml) to high (0.1 or 1g/ml) Tc concentration of 100:1 and 1000:1, the eDeg-On_2 
system enables reliable detection of changes in the number of cells above the 1% 
gate, and the number of actual hits is in agreement with the number of expected hits.  
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Table 2.2. Mock screen experiment 2 results. 
1% gate 2% gate 
1000:1 1000:1 
Sample 
# Cells above 1% 
gate 
# Expected 
hits 
# Actual 
hits 
Sample 
# Cells above 2% 
gate 
# Expected 
hits 
# Actual 
hits 
0.04 
only 
1031 - - 
0.04 
only 
2079 - - 
0.04+ 
0.1 
1044 4 13 
0.04+ 
0.1 
2152 15 73 
0.04+1 1068 19 37 0.04+1 2121 50 42 
100:1 100:1 
Sample 
# Cells above 1% 
gate 
# Expected 
hits 
# Actual 
hits 
Sample 
# Cells above 2% 
gate 
# Expected 
hits 
# Actual 
hits 
0.04 
only 
1003 - - 
0.04 
only 
2026 - - 
0.04+ 
0.1 
1011 44 8 
0.04+ 
0.1 
2112 146 86 
0.04+1 1204 190 201 0.04+1 2548 505 522 
 
To evaluate whether establishing a larger gate would help enrich the 
representation of actual hits in the total gated cells, a 2% gate was also set based on 
the top 2% of cells displaying the highest fluorescence among the population of cells 
Figure 2.9. Normalized GFP fluorescence of cells treated with different 
concentration of Tc.  
HEK293/eDeg-On_2 cells were treated with different concentrations of Tc 
(0.04, 0.1 and 1 g/ml). The mean GFP fluorescence was measured using flow 
cytometry and normalized to the GFP fluorescence of cells treated with the 
0.04 μg/ml Tc.  
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treated only with 0.04 μg/ml Tc. The number of cells above the 2% gate, the number 
of expected hits and the number of actual hits were quantified (Table 2.2). To 
compare the 2% gate and the 1% gate, the percentage of actual hits in the total 
population were calculated for the cell mixtures at 100:1 ratio (Table 2.3). The 
percentage increase from 1% to 2% gate, suggesting that increase in gating from 1% 
to 2% enriches the representation of hits in the gated population.  
Table 2.3. Comparison of gating in experiment 2.   
Sample 
# Actual hits 
above 1% gate 
# Actual hits 
above 2% gate 
% Actual hits above 
1% gate in the total 
population 
% Actual hits above 
2% gate in the total 
population 
0.04+0.1 8 86 0.008% 0.086% 
0.04+1 201 522 0.201% 0.522% 
 
2.4.3. Summary for Experiment 1 and 2 
The goal of the mock screens (experiment 1 and 2) was to evaluate the eDeg-
On_2 system as a reporter assay for the GeCKOv2 library screen. The robustness of a 
reporter assay is critical for conducting a pooled library-based screen and it is 
evaluated by quantifying the dynamic range and the signal-to-noise ratio (Hu and 
Luo, 2012). Experiment 1 was used to evaluate the dynamic range of the eDeg-On_2 
system by comparing the GFP fluorescence of cells transduced only with NT gRNA 
virus to the fluorescence of cells transduced only with tTA gRNA virus, and a 5.6-
fold increase in GFP fluorescence was observed with 0.04 μg/ml Tc. Another 
fluorescence-based assay reported a similar fold increase (6 fold) in fluorescence 
between negative and positive control in a GeCKO library screen (Timms et al., 
2016), suggesting that the dynamic range of the eDeg-On_2 system was suitable for 
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a GeCKO library screen. Another method was utilized to evaluate the dynamic range 
of the reporter assay. This method establishes a 1% or 2% gate by gating top 1% or 
2% cells with highest fluorescence in the negative control, and compares the 
percentage of cells in this gate in the positive control to the established 1% or 2% 
cells in the negative control. In the NT/tTA gRNA virus transduction experiment, 
with the 1% gate determined by the top 1% cells with highest fluorescence in NT 
gRNA virus transduced cells, the percentage of cells above the 1% gate for tTA gRNA 
transduced cells was found to 25.1% (25,129 cells in the 1% gate out of a total of 
100,000 cells) at 0.04 μg/ml Tc. Similarly, another reporter assay used in another 
GeCKO library screen reported an increase from 1% to 26.8% in transduced cells 
(Wu et al., 2016). Therefore the dynamic range of the eDeg-On_2 system satisfies the 
requirement of a CRISPR-based knockout screen.  
To evaluate the signal-to-noise ratio of the eDeg-On_2 system, different ratios 
of positive and negative controls were mixed and cell numbers in the top 1% gate 
were monitored using flow cytometry. Two different sets of positive and negative 
controls were used in the mock screens. The first set utilizes cells transduced only 
with tTA gRNA viruses as positive control and cells transduced only with NT gRNA 
viruses as negative control. Different ratios of NT and tTA gRNA viruses were then 
used to transduce cells to mock the different representations of strong proteasome 
activators in the library. These strong proteasome activators upon knockout are 
expected to have GFP fluorescence similar to the fluorescence of tTA knockouts. The 
result of the NT/tTA gRNA virus transduction experiment suggests that the eDeg-
On_2 system can detect a minimum of 120 gRNA hits among a library of about 
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120,000 gRNAs. If the library contains fewer than 120 hits, the noise of the eDeg-
On_2 system may result in a high rate of false negatives.  
The second set of positive and negative controls utilizes cells with higher 
fluorescence treated by a higher Tc concentration as positive control and cells with 
lower fluorescence treated by lower Tc concentration as negative control. Different 
ratios of cells treated with higher Tc concentration were mixed with cells treated 
with lower Tc concentration to mock the different representations of proteasome 
activators in the library. The result of the high/low Tc treatment experiment 
suggests that the eDeg-On_2 system is capable of detecting about 120 hits among a 
library of about 120,000 gRNAs if on average these 120 hits can introduce increased 
fluorescence beyond 2.5 fold. The signal-to-noise ratio is poor if fewer than 120 hits 
with increased fluorescence of 2.5 fold or 120 hits with increased fluorescence 
below 2.5 fold are present in the library.  
There are multiple possible methods to enhance the signal-to-noise ratio. 
Increasing library coverage is an effective approach to overcome poor signal 
resolution and to identify weaker hits present in pooled shRNA library screens 
(Strezoska et al., 2012). Increasing library coverage is also expected to facilitate the 
identification of hits characterized by low output signal or low representation in the 
context of a CRISPR-based library screen. Extending gating from 1% to 2% also 
enriches the representation of hits in the total population. Performing additional 
rounds of sorting is also expected to enrich the hits in the total population.  
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In summary, the results of the mock screens suggest that the eDeg-On_2 
system provides a robust reporter assay for the screen of proteasome activators 
upon knockout via transduction of the GeCKOv2 library.  
2.5. Screening with the GeCKOv2 Library 
2.5.1. Considerations for MOI and Gating 
HEK293/eDeg-On_2 cells will be transduced with the GeCKOv2 library and 
screened for selection of cells presenting increased fluorescence to isolate 
regulatory proteins that result in activation of proteasomal degradation upon 
knockout. The MOI and gating will be adjusted during sorting to tune the number of 
hits. The MOI determines the number of gRNAs in each cell. The gate will be 
determined by defining the cell population displaying highest fluorescence among a 
population of negative control cells that are transduced only with NT gRNA virus, as 
reported previously (Timms et al., 2016). The gating for sorting can also be 
determined by using the population of transduced cells with highest fluorescence 
(Wu et al., 2016 and DeJesus et al., 2016). Establishing the gate based on negative 
control cells will be more informative than directly establishing the gate with 
transduced cells, because the change in fluorescence of the hits can be compared 
directly to negative control cells.  
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2.5.2. Experimental Design 
A preliminary screen will be first conducted using HEK293/eDeg-On_2 cells 
transduced with the GeCKOv2 library at 10X library coverage (Figure 2.10), and the 
MOI and the gate to be used will be determined based on the percentage of actual 
hits of the gated population. An MOI of 0.2 and a 1% gate would be first tested to 
determine if the percentage of actual hits is between 0.01% (equivalent to 12 gRNA 
hits in a total library of 120,000 gRNAs) and 1% (equivalent to 1200 gRNA hits in a 
total library of 120,000 gRNAs). Three outcomes are possible: 
a) If the percentage of actual hits is above 1% of the total cell population, the 
gate will be lowered. If the percentage of actual hits still exceeds 1% with the 
0% gate, the final screen will be conducted with 500X library coverage, and 
the top 1% cells with highest fluorescence will be gated among cells 
transduced with the GeCKOv2 library.  
b) If the percentage of actual hits is between 0.01% and 1%, the final screen will 
be conducted with 500X library coverage at an MOI of 0.2. 
c) If the percentage of actual hits is below 0.01%, the gate will be increased to 
2%. If the percentage of actual hits is still below 0.01% with 2% gate, an MOI 
of 0.2 is not suitable for the screen with the GeCKOv2 library. 
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If performing transduction with an MOI of 0.2 does not result in an increase 
in the percentage of actual hits to 1%, the evaluation process will be repeated 
increasing the MOI to 1 (60% of cells is transduced with one or more gRNAs at MOI 
of 1). If a transduction with an MOI of 1 does not result in an increase in the 
percentage of cells above the 1% gate, an MOI of 5 will be tested, which corresponds 
to more than 99% of cells transduced with one or more gRNAs. If a transduction 
with an MOI of 5 still does not result in an increase the percentage of cells above the 
1% gate, the current eDeg-On_2 system is not suitable for conducting the screen of 
proteasome activators upon knockout via transduction of the GeCKOv2 library.  
The MOI and percentage of gating determined in the preliminary screen will 
be used to conduct the final screen at 500X coverage of the library (Figure 2.11). 
The gated population will be sorted, and hits will be enriched with additional 
rounds of sorting until the final population above the gate is more than 90% of the 
total cell population. Depending on the MOI used, different methods will be 
employed to obtain the gRNA representations as detailed below.  
Figure 2.10. Preliminary screen plan.  
The preliminary screen will be conducted with a smaller coverage compared with the 
final screen, and will determine the MOI and gating to be used in the final screen.  
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If an MOI of 0.2 is used, the DNA of the final sorted population will be 
extracted, followed by the amplification of the gRNA regions and the addition of 
barcodes through PCR for next-generation sequencing. Next-generation sequencing 
will be used to determine the gRNA representations, and the gRNA representation of 
sorted cells will be compared to the gRNA representation of unsorted cells. Genes 
will be ranked based on enrichment of gRNA representations upon sorting via one 
or more of the algorithms including RSA (König et al., 2007), RIGER (Luo et al., 
2008), HiTSelect (Diaz et al., 2015) and MAGeCK (Li et al., 2014). After gene ranking, 
the top ranked genes will be selected for validation as proteasome activators 
through counter screens, secondary assays, and other functional assays that detect 
UPS activation or study the specific function of these genes related to UPS.  
If an MOI larger than 0.2 is used, two options are available. The first option to 
identify potential proteasome regulators is to directly establish monoclonal 
populations from sorted cells and use next-generation sequencing to determine the 
Figure 2.11. Final screen plan.  
The final screen will be conducted at 500X coverage. Depending on the MOI determined in the 
preliminary screen, different methods to obtain and evaluate hits will be utilized.   
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proteasome activator(s) in each clone. Detailed steps of this option include: i) 
establish monoclonal populations from sorted cells; ii) extract genomic DNA from 
the monoclonal populations; iii) use next-generation sequencing to determine and 
compare gRNA representations of each monoclonal population to the unsorted 
population. One or few genes is expected to be highly enriched when comparing the 
unsorted population to the sorted population, and the gene or the combination of 
genes will be validated as proteasome activator(s) through counter screens, 
secondary assays, and other functional assays.  
The second option to identify potential proteasome regulators is to establish 
a secondary library from the top hits of the primary screen and conduct a secondary 
screen using the secondary library. In addition to the primary screen, sometimes a 
secondary screen is used to validate the result of the primary screen. A secondary 
library was developed based on the top-ranked 300 genes in a GeCKOv2 library 
primary screen, and hits discovered from the secondary screen strongly supported 
the result of the primary screen (DeJesus et al., 2016). Detailed steps of the second 
option include: i) perform steps from genome extraction to next-generation 
sequencing analysis as in the experiment conducted with an MOI of 0.2 and pick top 
300 genes to establish a secondary library via oligo synthesis and re-cloning of the 
most potent gRNA targeting each of these 300 genes. If oligo synthesis is not an 
option, obtain amplified gRNA regions from the primary screen without establishing 
monoclonal populations and re-clone into lentiviral plasmids to obtain a secondary 
library; ii) produce virus from the secondary library, transduce HEK293/eDeg-On_2 
cells with the same MOI and use the same gating for sorting; steps iii) and iv) are the 
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same as in the first option. The second option also shares the same expected 
outcomes and the validation of the hits through counter screens and secondary 
assays.  
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Chapter 3 
Summary and Future Work 
This project aims at optimizing the eDeg-On system and evaluating it for the 
discovery of proteasome activators through CRISPR-mediated whole-genome 
knockout screens. This goal was achieved by generating a stable cell line expressing 
the eDeg-On circuit that is compatible with CRISPR-cas system, and by evaluating 
this cell line for high-throughput screens. The stable cell line resulting from 
chromosomal integration of the eDeg-On circuit into HEK293 cells was validated by 
testing the GFP output signal in response to the inducer tetracycline, the 
proteasome inhibitor MG132, and the proteasome activators PSMD11 and PSMD11-
S14D. A mock screen was also conducted by testing the response of the stable cell 
line to transduction with virus particles expressing gRNA specific for the gene 
encoding tTA and non-targeting gRNA to evaluate the use of this system in the 
contest of a high throughput screen.  
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3.1. Developing of the Stable Cell Line of the eDeg-On System 
The eDeg-On_2 system is comprised of three components in three plasmids. 
The TO_GFP plasmid encodes the GFP gene downstream of the TO that results in 
regulation of GFP expression upon binding of tTA. A stable cell line with the TO_GFP 
component (pTO_GFP) was first generated via transfection, antibiotic selection for 
stable integration, and sorting for GFP-expressing cells with highest fluorescence. 
The two tTA plasmids (ptTA_2 and pTRE_tTA) were transfected into the newly 
developed HEK293/TO_GFP_2 cell line, followed by antibiotic selection for stable 
integration, and isolation of single clones with low GFP fluorescence.  
Isolated HEK293/eDeg-On single clones were first tested in the presence of 
Tc, and single clones presenting increase in GFP fluorescence upon addition of Tc 
equal or higher than half of the theoretical expected increase were selected for 
further analyses. Selected clones were then evaluated in the presence of Tc for 
proteasome inhibition and activation. Most clones demonstrated a 1.6-fold or higher 
decrease in GFP fluorescence in response to the proteasome inhibitor MG132. Clone 
198 was selected as a candidate to test its response to the proteasome activator 
PSMD11 and PSMD11-S14D, and approximately 1.3- and 1.4-fold increase in GFP 
were observed, respectively.  
In summary, the following procedures for establishing and selecting a 
candidate clone for the eDeg-On system are recommended: 1) establish a 
monoclonal population of HEK293 cells stably transfected for the expression of the 
pTO_GFP plasmid that presents the highest GFP expression; 2) transfect the two tTA 
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plasmids (ptTA_2 and pTRE_tTA) into the newly developed cell line cell line at a 
ratio of 10:1; 3) isolate single clones of the resulting cell line; 4) test the response of 
the isolated clones to Tc dosage to select clones with the highest fold change in GFP 
signal; 5) establish the Tc dosage curve for the clones selected; 6) test the response 
of the clones selected to the proteasome inhibitor (MG132) and activators (PSMD11 
and PSMD11-S14D) using the Tc concentration resulting in highest sensitivity to 
changes in UPS activity; 7) verify GFP and tTA protein levels via Western blot.  
3.2. Verifying CRISPR-mediated Knockout Controls 
One positive control and one negative control were designed to test the 
efficacy of CRISPR-mediated knockout in cells expressing the eDeg-On_2 system. The 
result of the transduction experiment performed using tTA gRNA virus to knockout 
tTA from the eDeg-On_2 system supported my hypothesis: tTA knockout removed 
the function of tTA as a regulator in the eDeg-On_2 system; as a result, the GFP 
fluorescence of cells transduced with viruses expressing tTA-specific gRNA was 
found unchanged upon Tc dosage. 
3.3. Titrating CRISPR-mediated Knockout Virus 
Different methods for virus titration were proposed: the RNA titration 
method based on the measurement of viral particles in the supernatant is the most 
straightforward method, although it may overestimate the real titer by counting in 
defective viral particles. The DNA titration method is more accurate than the RNA 
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titration method, and is not limited by the expression of the transgene; however, the 
choice of the primers to amplify the sequences in the transgene is critical and 
unspecific binding of the primers in the genome can also lead to overestimation of 
the titer. The functional titration method is the most accurate method, because the 
expression of the transgene is the desired output for most experiments.  
The virus titration was conducted by quantifying the antibiotic resistance 
marker gene, and the quantification was performed by counting the number of 
surviving cells after antibiotic selection to calculate cell viability. The accuracy of 
quantification of cell viability based on mere counting could be enhanced by 
including more replicates. Alternatively, the number of viable cells could also be 
determined by quantifying the concentration of ATP as an indicator of metabolically 
active cells.   
3.4. Mock Screen in HEK293/eDeg-On_2 Cells 
The robustness of the HEK293/eDeg-On_2 cell line was evaluated through 
two mock screens by either introducing CRISPR-mediated knockouts into cells to 
induce changes in fluorescence or directly modulating Tc concentrations to tune the 
fluorescence of cells. In the first mock screen, one negative control and one positive 
control were mixed at different ratios to mimic the representation of hits in a real 
screen, and this positive control (tTA knockout) mimics the theoretical strongest 
proteasome activator that results in maximal degradation of tTA. Tc-induced 
HEK293/eDeg-On_2 cells with different levels of GFP fluorescence were used as 
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positive controls in the second mock screen, and these positive controls mimic 
potential proteasome activators of varying strength capable of inducing different 
levels of GFP fluorescence.  
3.5. Validation of Hits from the GeCKOv2 Screen 
Identified hits from the GeCKOv2 screen will be first validated through 
CRISPR-mediated knockout to confirm that the expression of the gene(s) of interest 
is reduced by the knockout. Selected genes will be verified individually via 
lentivirus-mediated knockout. Sequence analysis of the endogenous gene will be 
performed to verify the presence of indel mutations introduced by CRISPR-
mediated genome editing, and gene expression will be examined at the 
transcriptional and the post-translational level by qRT-PCR and Western blot 
analyses. The influence of individual knockout on the eDeg-On_2 system will also be 
evaluated by monitoring GFP fluorescence of HEK293/eDeg-On_2 cells transduced 
with lentivirus containing gRNA targeting the gene of interest, and comparing with 
the GFP fluorescence of cells transduced with non-targeting gRNA virus.  
Genes selected using the primary screen will be validated through a series of 
counter screens and secondary assays to confirm their identity as true proteasome 
activators upon CRISPR-mediated knockout. Individual gene knockouts will be first 
verified in HEK293/eDeg-On_2 cells co-expressing iRFP to confirm that CRISPR-
mediated knockout results in increase GFP/iRFP ratio. To verify the function of the 
genes selected, a series of counter screens and secondary assays will also be 
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performed. Selected hits will be tested via CRISPR-mediated knockout in the context 
of: i) the eDeg-On system based on wild type TetR without any degron tag to 
eliminate false positives that may induce increase in GFP fluorescence by 
downregulating TetR expression or upregulating GFP expression; ii) a direct 
reporter consisting of GFP fused to a degradation tag (GFP-Deg) to verify that 
knockout of selected genes induces degradation of tTA-Deg rather than changes in 
tTA or GFP expression; iii) a GFP-Deg reporter under the control of a signal 
sequence to direct expression in the secretory pathway (Link et al., 2005) to test 
whether selected genes affect ERAD in addition to proteasomal degradation; iv) the 
αsyn-split GFP assay (Kothawala et al., 2012) to quantify changes in aggregation of 
the misfolding-prone protein α-synuclein and counter select genes that increase GFP 
output by enhancing protein aggregation.  
 
In summary, I validated the HEK293/eDeg-On_2 cell line as a platform to 
quantify changes in proteasomal degradation. These results will inform the design 
of CRISPR-mediated whole-genome knockout screens to isolate proteasome 
regulators, which will open the way to the development of therapeutic approaches 
for diseases characterizes by accumulation of misfolded proteins.  
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Chapter 4 
Materials and Methods 
4.1. Chemicals and Reagents 
Tetracycline (Tc) was purchased from Invitrogen. MG-132 was purchased 
from Fisher Scientific. Zeocin, blasticidin and puromycin were purchased from 
Invivogen, hygromycin B from Gold Biotechnology and Geneticin (G418) from 
Sigma-Aldrich.  
High-glucose Dulbecco's modified eagle's medium (DMEM) and penicillin 
streptomycin glutamine (PSQ) were purchased from GE Healthcare, fetal bovine 
serum (FBS) was from Sigma-Aldrich, PBS was purchased from Lonza, and TrypLE 
was from Life Technologies. The JetPrime transfection reagents were purchased 
from Polyplus Transfection. 
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4.2. Plasmid Construction 
The ptTA_2 plasmid was constructed by replacing the puromycin resistance 
cassette in the ptTA plasmid (Zhao et al., 2014) with the hygromycin resistance 
cassette using the restriction enzymes PstI and BlpI (New England Biolabs).  
The pQTEV-PSMD11 plasmid was purchased from Addgene. The PSMD11 
cassette was cloned from the pQTEV-PSMD11 plasmid to the pcDNA3.1+ backbone 
(Invitrogen) using restriction enzymes BamHI and NotI (New England Biolabs). The 
S14D mutation was introduced into the PSMD11 gene via site-directed mutagenesis 
using primers (forward: 5’- AGTTCCAGAGAGCCCAGGACCTACTCAGCACCGACCG-3’ 
and reverse: 5’-CGGTCGGTGCTGAGTAGGTCCTGGGCTCTCTGGAACT-3’).  
The nontargeting (NT)-, USP14- and tTA-gRNA plasmids were constructed as 
previously described (Shalem et al, 2014 and Sanjana et al., 2014). Briefly, the 
gRNAs targeting genes were designed using the online software CRISPR Design 
(http://crispr.mit.edu/). Paired gRNA oligos (NT: 5’-
CACCGACGGAGGCTAAGCGTCGCAA-3’ as forward and 5’-
CTGCCTCCGATTCGCAGCGTTCAAA-3’ as reverse; tTA: 5’-
CACCGCTTAATGAGGTCGGAATCGA-3’ as forward and 5’- 
CGAATTACTCCAGCCTTAGCTCAAA-3’ as reverse; USP14: 
CACCGgctcagctgtttgcgttgac-3’ as forward and 5’-gtcaacgcaaacagctgagcCAAA-3’ as 
reverse) for each gene were then annealed and cloned into the plentiCRISPRv2 
backbone (Addgene) using the restriction enzyme BsmBI (Fermentas).  
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4.3. Cell Culture and Transfection 
Human embryonic kidney cell line 293 (HEK293), HEK293 with SV40 large T 
antigen stable integration (HEK293T) and HEK293 derived stable cell lines were 
maintained in high-glucose DMEM medium supplemented with 10% FBS and 1% 
PSQ, and were passaged every other day at split ratios ranging from 1:6 to 1:12 to 
prevent cells from reaching 90% confluency. HEK293 derived stable cell lines were 
cultured in medium supplemented with appropriate antibiotics once in every three 
passages to ensure the stability of the new cell line.  
Cells were transfected using JetPrime transfection reagents according to the 
manufacturer’s protocol. Briefly, cells were plated at 50% confluency 22-26 hours 
prior to transfection. Cells were supplemented with JetPrime buffer, plasmid DNA, 
and JetPrime reagent mixtures on the day of transfection, and the medium was 
replaced 24 hours after transfection.  
4.4. HEK293/eDeg-On_2 Stable Cell Line Generation 
HEK293 cells were transiently transfected with the linearized TO_GFP 
plasmid (Zhao et al, 2014) and stably transfected cells were selected using medium 
containing zeocin (150 g/ml) for 3 weeks. The cells displaying the highest 
fluorescence (20% of the total population) were selected using fluorescence-
activated cell sorting (FACS). The resulting population was transiently transfected 
with linearized ptTA and pTRE_tTA plasmids at 1:5 ratio. Stably transfected cells 
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were selected using medium containing hygromycin (200 g/ml) and blasticidin (3 
g/ml) for 3 weeks. Selected cells were subcultured in 96-well plates to isolate 
monoclonal populations of HEK293 expressing the eDeg-On_2 system 
(HEK293/eDeg-On_2 cells).  
4.5. Virus Production, Titration and Transduction 
HEK293T cells below passage 10 were plated into T175 flasks (Greiner Bio-
one) one day prior to transfection at 60-70% confluency. Cells were transfected 
with the envelope plasmid (pMD2.g), the packaging plasmid (psPAX2) and the 
plasmid of interest according to the manufacturer’s protocols (Polyplus transfection) 
at a ratio of 5:7.5:10 in a 20 μg DNA solution. The medium was replaced with fresh 
medium 7 hours post-transfection and virus was harvested from the medium after 
48 hours by filtration using a 0.45 m filter (EMD Millipore Corp) and concentrated 
using the LentiX concentrator (Clontech) according to the manufacturer’s protocols. 
Virus was aliquoted and stored at -80 °C.  
Virus was titrated as described previously (Sastry et al., 2002). Briefly, the 
viral RNA was extracted using the ZR Viral RNA Kit (Zymo Research) and converted 
to cDNA using the QuantiTect Rev. Transcription Kit (Qiagen). The concentration of 
viral cDNA was determined using quantitative PCR (qPCR).  
The MOI was determined as previously described (Shalem et al., 2014). 
Briefly, cells were plated in 12-well plate at 60% confluency. Cells were transduced 
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with different volumes of concentrated virus ranging from 0 (control) to 20 l per 
well in the presence of 4 g/ml Polybrene (Sigma-Aldrich) after 24 hours and split 
into duplicate wells the next day. Cells in one replicate well were selected with 0.5 
μg/ml of puromycin while cells in the other well were maintained in medium 
without puromycin. The volume of virus corresponding to an MOI of 0.2 was 
determined as the volume of virus corresponding to 20% cell viability upon 
antibiotic selection.  
To transduce HEK293/eDeg-on_2 cells with virus expressing the gRNA 
HEK293/eDeg-on_2 cells were plated at 60% confluency one day prior to 
transduction and transduced with the gRNA virus at an MOI of 0.2 in the presence of 
8 g/ml of Polybrene. Cells were replaced with fresh media 24 hours post-
transduction, and stably transduced cells were selected using medium containing 
0.5 g/ml puromycin for 7 days.  
4.6. T7EI Analysis 
The genomic DNA of cells modified via CRISPR-cas technology was extracted 
using the E.Z.N.A Tissue DNA Kit according to manufacturer’s protocols (Omega Bio-
tek). The T7EI assay was performed as previously described (Kim et al., 2009). 
Briefly, the USP14-modified genomic region was amplified via PCR and gel-purified 
using the Gel/PCR DNA Fragments Extraction Kit according to manufacturer’s 
protocols (IBI Scientific). A total of 400 ng of purified PCR product was hybridized 
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and reannealed to allow the formation of heteroduplex DNA using the following PCR 
cycles: 5min of denaturation at 95 ºC, followed by fast cooling to 85 ºC at -2 ºC /s, 
and slow cooling to 25 ºC at -0.1 ºC /s. The heteroduplex DNA was incubated with 3 
units of T7 Endonuclease I (New England Biolabs) for 45 min and the reaction was 
terminated by adding 1l of 0.25M EDTA per 200 ng of DNA. Signs of T7EI-digested 
DNA were examined on a 1.5% agarose gel.  
4.7. Flow Cytometry Analysis 
Cells were analyzed with a FACSCanto II flow cytometer (BD, San Jose, CA) to 
measure fluorescence intensity of GFP (488 nm laser, 530/30 nm emission filter) 
and iRFP (640 nm laser, 660/20 emission filter). At least 10,000 cells were recorded 
in each sample for analysis. 
For transient transfection experiments, we monitored changes in GFP signal 
within iRFP-positive cells to monitor changes in GFP signal within transfected cells. 
The reported output signal was calculated by normalizing GFP to iRFP signal to 
eliminate differences arising from transfection efficiencies. 
4.8. Quantitative PCR 
Quantitative PCR was performed using viral cDNA as template, primers 
specific for the cas9 gene in the viral genome (forward: 5’- 
CGTGACCGAGGGAATGAGAAAGC-3’ and reverse: 5’-AGCAGATCGTGGTATGTGCCC-3’), 
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and PerfeCTa SYBR Green FastMix (Quanta Biosciences) according to 
manufacturer’s protocols. Standards of qPCR were generated via serial dilutions of 
linearized plentiCRISPR plasmids with known cas9 copy numbers. PCR reactions 
were performed using a CFX96 Real-Time PCR Detection System (Bio-Rad) as 
follows: one cycle of 2 min at 95 °C, followed by 40 cycles of 1s at 95 °C, 30s at 60 °C, 
and 30s at 72 °C. Result analysis was performed using the CFX Manager software 
(Bio-Rad).  
4.9. Statistical Analyses 
Data were presented as arithmetic mean ± standard deviation of at least 
three biological replicates unless otherwise stated. Statistical significance was 
determined by the Student’s t-test assuming two tails and equal variance.  
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